

InforMEDical

Informing Medical Practice

- [CME Information](#)
- [Table of Contents](#)
 - [Overview](#)
- [Biology: focus on new agents](#)
 - [Molecular subsets](#)
 - [Update on IL-2](#)
- [Immune checkpoint blockade](#)
 - [VEGF inhibitors](#)
- [P13 kinase pathway inhibitors](#)
- [Combination vs sequential therapy](#)
 - [Novel targeted treatments](#)
- [Biomarkers for targeted therapies](#)
 - [Neoadjuvant therapy](#)
 - [VEGF pathway resistance](#)
 - [Register & Receive CME Credit](#)
 - [Download PDF \(All Chapters\)](#)
- [InforMEDical Home](#)

InforMEDical

Communications, Inc.

83 Acton Street

Carlisle, MA 01741

tel: 978-318-9582

fax: 978-318-9583

info@informedmedicalcme.com

Innovations and Challenges in Renal Cancer

A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.

InforMEDical Communications, Inc. • 83 Acton Street • Carlisle, MA 01741

tel: 978-318-9582 • fax: 978-318-9583 • email: info@informedmedicalcme.com

References

Update on the Role of IL-2 for Metastatic Kidney Cancer

Gleave ME, Ehilali M, Fradet Y, et al: Canadian Urologic Oncology Group: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. *N Engl J Med*. 1998; 338: 1265-1271.

Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. *Br J Urol*. 1989; 63:128-131.

Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. *J Urol*. 1992;148:1247-1248.

Marten A, Flieger D, Renoth S, et al: Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. *Cancer Immunol Immunother*. 2002; 51: 637-644.

Chang AE, Li Q, Jiang G, et al: Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. *J Clin Oncol*. 2003; 21: 884-890.

McDermott DF, Rini BI. Immunotherapy for metastatic renal cell carcinoma. *Br J Urol*. 2007; 99: 1282-1288.

Gitlitz BJ, Beldegrun AS, Figlin RA. Vaccine and gene therapy of renal cell carcinoma. *Semin Urol Oncol*. 2001; 19: 141-147.

Lesimple T, Moison A, Guille F, et al: Treatment of metastatic renal cell carcinoma with activated autologous

- macrophages and granulocyte-macrophage colony-stimulating factor. *J Immunother.* 2000; 23: 675-679.
- Schwabb T, Heaney JA, Schned AR, et al: A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. *J Urol.* 2000; 163: 1322-1327.
- Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. *N Engl J Med.* 2000; 343: 750-758.
- Childs R, Srinivasan R. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors. *Cancer J Sci Am.* 2002; 8: 2-11.
- Rini BI, Zimmerman T, Stadler WM, et al: Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. *J Clin Oncol.* 2002; 20: 2017-2024.
- Rosenberg SA, Mule JJ, Spiess PJ, et al: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. *J Exp Med.* 1985; 161: 1169-1188.
- Mule JJ, Yang JC, Lafreniere RL, et al: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. *J Immunol.* 1987; 139: 285-194.
- Escudier B, Eisen T, Stadler W, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med.* 2007; 356(2) :125-134.
- Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med.* 2007;356(2):115-124.
- Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. *N Engl J Med.* 2007 :356(22) :2271-2281.
- Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind Phase III trial. *Lancet.* 2007; 370(9605): 2103-2111.
- Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. *J Clin Oncol.* 1995; 13: 688-696.
- Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant Interleukin-2 in patients with renal cell carcinoma. *Cancer J Sci Am.* 2000;6:S55-S57.
- Rosenberg SA, Yang JC, White DE, et al: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. *Ann Surg.* 1998; 228: 307-319.
- Beldegrun A, Webb DE, Austin HA III, et al: Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. *J Urol.* 1989; 141: 499-503.
- Margolin KA, Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. *J Clin Oncol.* 1989; 7: 486-498.
- Neidhart JA. Interferon therapy for the treatment of renal cancer. *Cancer.* 1986;57:1696-1699.
- Muss HB. Interferon therapy for renal cell carcinoma. *Semin Oncol.* 1987; 14: 36-42.
- Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. *J Clin Oncol.* 2006; 24: 5584-5592.
- Muss HB, Costanzi JJ, Leavitt R, et al: Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. *J Clin Oncol.* 1987; 5: 286-291.
- Négrier S, Caty A, Lesimple T, et al: Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. *J Clin Oncol* 2000; 18: 4009-4015.
- Medical Research Council and Collaborators. Interferon alfa and survival in metastatic renal carcinoma: early results of a randomised controlled trial. *Lancet.* 1999; 353: 14-17.
- Pyrhonen S, Salminen E, Ruutu M, et al: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. *J Clin Oncol.* 1999; 17: 2859-2867.
- Coppin C, Porzolt F, Awa A, et al: Immunotherapy for advanced renal cell cancer. *Cochrane Database Syst Rev.* 2005; 1: CD001425.

- Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. *N Engl J Med*. 1998; 338: 1272-1278.
- Yang JC, Sherry RM, Stienberg SM, et al: A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. *J Clin Oncol*. 2003; 21: 3127.
- McDermott DF, Regan MM, Clark JI, et al: A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. *J Clin Oncol*. 2005; 23: 133-141.
- Negrier S, Perol D, Ravaud C, et al: Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial. *Cancer*. 2007; 110: 2468-2477.
- Cangiano T, Liao J, Naitoh J, et al: Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. *J Clin Oncol*. 1999; 17: 523-528.
- Motzer RJ, Bacil J, Mariani T, et al: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. *J Clin Oncol*. 2002; 20: 2376-2381.
- Upton MP, Parker RA, Youmans A, et al: Renal cell carcinoma: histologic predictors of cytokine response. *J Immunother*. 2005; 28: 488-495.
- Bui MHT, Seligson D, Han K, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. *Clin Cancer Res*. 2003; 9: 802-811.
- Atkins M, Regan M, McDermott D, et al: Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. *Clin Cancer Res*. 2005; 11: 3714-3721.
- Pantuck AJ, Fang Z, Liu X, et al: Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. *Proc Am Soc Clin Oncol*. 2005; 4: 535.
- Jaeger E, Waldman R, Roydasgupta T, et al: Array-based comparative genomic hybridization identifies chromosomal imbalances between interleukin-2 complete and non-responders. *J Clin Oncol*. 2008; 26(May 20 suppl): Abstract 5043.
- McDermott DF, Ghebremichael MS, Signoretti S, et al: The high-dose Aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). *J Clin Oncol*. 2010; 28: 15s: Abstract 4514.
- Schwarzberg T, Regan MM, Liu V, et al: Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy. *J Clin Oncol*. 2008; 26(May 20 suppl): Abstract 5044.
- Dandamudi UB, Ghebremichael MS, Sosman JA, et al: A Phase II study of bevacizumab and high dose bolus aldesleukin (IL-2) in metastatic renal cell carcinoma patients: A Cytokine Working Group Study.. *J Clin Oncol*. 2010; 28:15s: Abstract 4530.
- Rini BI, Halabi S, Rosenberg JE, et al: CALGB 90206: a Phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. *Proceedings of the ASCO Genitourinary Cancers Symposium*. 2008; Abstract 350.
- Avigan DE, Vasir B, George DJ, et al: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. *J Immunother*. 2007; 30: 749-761.
- Oosterwijk-Wakka JC, Tiemessen DM, et al: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. *J Immunother*. 2002; 25: 500-508.
- Wierecky J, Muller MR, Wirths S, et al: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. *Cancer Res*. 2006; 66: 5910-5918.
- Yang JC, Hughes M, Kammula U, et al: Impilimumab (anti-CLTA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. *J Immunother*. 2007; 30: 825-830.
- Brahmer JR, Topalian S, Wollner I, et al: Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. *J Clin Oncol*. 2008; 26 (May 20 suppl): Abstract 3006.
- Sznol M, Powderly JD, Smith DC, et al: Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. *J Clin Oncol*. 2010; 28:15s:

Abstract 2506.

Morris JC, Shapiro GI, Tan AR, et al: Phase I/II study of GC1008: a human anti-transforming growth factor-beta monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. J Clin Oncol. 2008; 26(May 20 suppl): Abstract 9028.

Sznol M, Hodi FS, Margolin K, et al: Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer. J Clin Oncol. 2008; 26(May 20 suppl): Abstract 3007.

Schmidt H, Selby P, Mouritzen U, et al: Subcutaneous dosing of recombinant human interleukin-21 is safe and has clinical activity: results from a dose-escalation study in stage 4 melanoma and renal cell cancer. J Clin Oncol. 2008; 26(May 20 suppl): Abstract 3041.

Moore DJ, Hwang J, McGreivy J, et al: Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. J Clin Oncol. 2005; 23:(June 1 suppl): Abstract 2503.

Prieto PA, Yang JC, Sherry RM, et al Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma. J Clin Oncol. 2010; 28:15s: Abstract 8544.

[Return to text](#)

copyright 2013, InforMEDical